NASDAQ:IDYA IDEAYA Biosciences Q3 2026 Earnings Results & Report $31.80 +0.17 (+0.52%) As of 11:36 AM Eastern This is a fair market value price provided by Massive. Learn more. IDEAYA Biosciences missed analyst earnings expectations but beat on revenue in its Q3 2026 results, released November 3, 2026. The company reported EPS of -$1.22 versus the -$1.18 consensus estimate, while revenue of $10.24 million topped the $7.58 million estimate by $2.66 million. Revenue increased 14.6% year over year. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 3, 2026TimeBefore Market OpensConference Call6:00 AM ET IDEAYA Biosciences EPS ResultsActual EPS-$1.22Consensus EPS -$1.18Beat/MissMissed by -$0.04One Year Ago EPS$1.33EPS Beat Rate2 of last 8 quartersIDEAYA Biosciences Revenue ResultsActual Revenue$10.24 millionExpected Revenue$7.58 millionBeat/MissBeat by +$2.66 millionYoY Revenue Growth+14.60%Upcoming EarningsIDEAYA Biosciences' Q4 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) IDEAYA Biosciences Q3 2026 Earnings FAQ Did IDEAYA Biosciences beat earnings estimates for Q3 2026? IDEAYA Biosciences (NASDAQ:IDYA) reported earnings of -$1.22 per share for Q3 2026, missing the consensus estimate of -$1.18. The report was announced on Tuesday, November 3, 2026. What was IDEAYA Biosciences' revenue for Q3 2026? IDEAYA Biosciences reported revenue of $10.24 million for Q3 2026, against a consensus estimate of $7.58 million. When is IDEAYA Biosciences' next earnings date? IDEAYA Biosciences' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for IDEAYA Biosciences on the company's earnings history page. IDEAYA Biosciences Earnings HeadlinesIDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Tops Revenue Estimates3 hours ago | finance.yahoo.comIDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business UpdateNovember 3 at 6:00 AM | prnewswire.comWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he says has never existed before. In a similar setup in the past, select investors saw $1,000 turn into over $1 million within a few years. Del Real just released a full video breakdown of what is driving this move and how to prepare.November 3 at 1:00 AM | Digest Publishing (Ad)Is IDEAYA Biosciences (IDYA) A Bargain Following Its ESMO 2026 Clinical Data?October 31 at 5:11 AM | finance.yahoo.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 30, 2026 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Stock Rated "Moderate Buy" by Wall Street AnalystsOctober 29, 2026 | americanbankingnews.comSee More IDEAYA Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IDEAYA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IDEAYA Biosciences and other key companies, straight to your email. Email Address About IDEAYA BiosciencesIDEAYA Biosciences (NASDAQ:IDYA) (NASDAQ:IDYA) is a biotechnology company focused on discovering and developing precision medicines for cancer. Its research emphasizes synthetic lethality, biomarker-driven drug discovery and molecularly defined patient populations, with the goal of matching targeted therapies to specific genetic alterations in tumors. The company’s pipeline includes darovasertib, an investigational protein kinase C inhibitor being studied primarily for genetically defined cancers, including metastatic uveal melanoma. IDEAYA is also developing IDE397, an investigational MAT2A inhibitor intended for tumors with MTAP gene deletion, as well as additional targeted oncology programs at earlier stages of development. Founded in 2015 and headquartered in South San Francisco, California, IDEAYA advances its programs through internal research, clinical development and collaborations with pharmaceutical and biotechnology partners. Its candidates remain investigational and are subject to clinical testing and regulatory review.View IDEAYA Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Are the Fears Around Alphabet’s Search Slowdown Warranted?Streaming Success: Fox Corp Channels Tubi For Q1 Earnings BeatCheck Point's Turnaround Could Be Closer Than Investors ThinkCaterpillar’s Sell-Off: Is the Market Missing Its AI Power Play?AbbVie's Humira Era Is Fading, But Its New Growth Engines Face Another TestAlphabet’s $400 Billion Sell-Off Could Be the Best AI Buying Window Left in 2026Exxon's Refining Profits Soared—Did Chevron Get the Same Windfall? Upcoming Earnings McDonald's (11/4/2026)DoorDash (11/4/2026)MercadoLibre (11/4/2026)Cenovus Energy (11/4/2026)Aflac (11/4/2026)Allstate (11/4/2026)MetLife (11/4/2026)Manulife Financial (11/4/2026)Cencora (11/4/2026)CVS Health (11/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
